Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Equity Ratio: 2023-2024

Historic Equity Ratio for Silence Therapeutics (SLN) over the last 2 years, with Dec 2024 value amounting to 0.66.

  • Silence Therapeutics' Equity Ratio was N/A to 0.50 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.11, marking a year-over-year change of. This contributed to the annual value of 0.66 for FY2024, which is 259.22% up from last year.
  • Per Silence Therapeutics' latest filing, its Equity Ratio stood at 0.66 for FY2024, which was up 259.22% from 0.18 recorded in FY2023.
  • Silence Therapeutics' Equity Ratio's 5-year high stood at 0.66 during FY2024, with a 5-year trough of 0.18 in FY2023.